Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
Aims/hypotheses Current evidence indicates that statins increase the risk of incident diabetes; however, the relationship between statins and glycaemic control in people with established diabetes has not been well characterised. To address this question, we conducted a meta-analysis of randomised controlled trials (RCTs) of statins in patients with diabetes for whom there was available data on glycaemic control.Methods We identified studies published between January 1970 and November 2013 by searching electronic databases and reference lists. We included RCTs in which the intervention group received statins and the control group received placebo or standard treatment, with >200 participants enrolled, with the intervention lasting >12 weeks and with pre- and post-intervention HbA1c reported. We combined study-specific estimates using random-effects model meta-analysis.Results In a pooled analysis of nine trials involving 9,696 participants (4,980 statin, 4,716 control) and an average follow-up of 3.6 years, the mean HbA1c of participants randomised to statins was higher than those randomised to the control group: mean difference (95% CI) was 0.12% (0.04, 0.20) or 1.3 mmol/mol (0.4, 2.2); p = 0.003. There was moderate heterogeneity across the studies (I (2) = 54%, p = 0.014) not explained by available study-level characteristics. This review was limited by the small number of studies, available data on only three statins and sparse reporting on changes in use of glucose-lowering medications.Conclusions/interpretation Statin treatment is associated with a modest increase in HbA1c in patients with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“among patients with T2DM, the increase in glucose has also been shown to be rather modest, with an increase in mean glycated hemoglobin (HbA1c) level of 0.12% (95% CI, 0.04–0.20) over a mean follow-up of 3.6 years in a pooled analysis of 9 trials involving 9696 participants.119”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“The I(2) statistic estimates the percentage of total variation across studies due to a true difference rather than chance [32].”
BackgroundBias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“We pooled the mean HbA1c difference across the studies (and subgroups) using random-effects model meta-analysis, which makes allowance for between-study heterogeneity [29].”
MethodQuantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“The Q statistic is the χ(2) test for heterogeneity with a degree of freedom equal to one minus the number of studies included in meta-analysis; this assesses whether observed differences in results between studies are due to chance alone [31].”
BackgroundAssessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · cited 1×
“The quality of the studies was assessed using US Preventive Task Force quality rating criteria for RCTs, the Jadad score [28].”
MethodDetection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · cited 1×
“3% for individuals randomised to rosuvastatin vs control [7, 36].”
BackgroundThe Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · cited 4×
“For instance, in the Collaborative Atorvastatin Diabetes Study (CARDS), 20% of the participants randomised to the statin arm vs 17% of those randomised to the control arm were switched to insulin or had insulin added to their treatment regimen by the end of the follow-up period [25].”
BackgroundMethodInfluentialRosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
(2003) · The Lancet · doi:10.1016/s0140-6736(03)13636-7 · Cited by 2,876 · cited 3×
“014) Subtotal Collins et al [23] Tajima et al [26]”
BackgroundMethodCollaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436 · cited 2×
“02% higher HbA1c level]), is smaller than the effect of statin use on the risk of new-onset diabetes reported in a previous meta-analysis of randomised clinical trials (approximately 10% increase in risk) [6].”
BackgroundCollaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081 · cited 8×
“C ol lin s et al ,2 00 3 [2 3] U K H PS Si m va :4 0 54 4/ 54 3 70 N R 1 an d 2 4.”
BackgroundInfluentialPreiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390 · cited 1×
“The effect of statins on incident diabetes appears to differ by dose and type, with higher doses conferring higher risk than lower doses [8] and with atorvastatin and rosuvastatin being associated with a higher risk than pravastatin [9].”
BackgroundRay, K. K., Seshasai, S. R. K., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Preiss, D., Erqou, S., & Sattar, N. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60697-8 · Cited by 1,383 · cited 2×
“12% increase in HbA1c would not be expected to have material effect on cardiovascular disease risk [35].”
BackgroundSelf-citationKnopp, R. H., d’Emden, M., Smilde, J. G., Pocock, S. J., & on behalf of the ASPEN Study Group (2006) · Diabetes Care · doi:10.2337/dc05-2415 · Cited by 550
Collins, R., Armitage, J., Parish, S., Sleight, P., & Peto, R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12475-0 · Cited by 492
Risk of incident diabetes among patients treated with statins: population based study
Carter, A. A., Gomes, T., Camacho, X., Juurlink, D. N., Shah, B. R., & Mamdani, M. M. (2013) · BMJ · doi:10.1136/bmj.f2610 · Cited by 404 · cited 1×
“The effect of statins on incident diabetes appears to differ by dose and type, with higher doses conferring higher risk than lower doses [8] and with atorvastatin and rosuvastatin being associated with a higher risk than pravastatin [9].”
BackgroundDirect Effect of Cholesterol on Insulin Secretion
Hao, M., Head, W. S., Gunawardana, S. C., Hasty, A. H., & Piston, D. W. (2007) · Diabetes · doi:10.2337/db07-0056 · Cited by 319
Nakata, M., Nagasaka, S., Kusaka, I., Matsuoka, H., Ishibashi, S., & Yada, T. (2006) · Diabetologia · doi:10.1007/s00125-006-0269-5 · Cited by 293 · cited 1×
“In addition, statins may be associated with increased insulin resistance [4, 17, 37–41].”
BackgroundFreed, M. I., Ratner, R., Marcovina, S. M., Kreider, M. M., Biswas, N., Cohen, B. R., & Brunzell, J. D. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02659-0 · Cited by 238 · cited 6×
“Data analysis Of the nine clinical trials included in the present analysis, three [20, 21, 27] reported their results in two subgroups (Table 1); we analysed these separately, giving a total of 12 data points in the meta-analysis.”
BackgroundMethodInfluentialYada, T., Nakata, M., Shiraishi, T., & Kakei, M. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702397 · Cited by 229
The Effect of Aggressive Versus Standard Lipid Lowering by Atorvastatin on Diabetic Dyslipidemia
The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1335 · Cited by 128
An assessment by the Statin Diabetes Safety Task Force: 2014 update
Maki, K. C., Ridker, P. M., Brown, W. V., Grundy, S. M., & Sattar, N. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.02.012 · Cited by 119 · cited 3×
“Possible explanations for the observed weaker effect of statin use on HbA1c concentration in diabetes include bias due to differential attrition or adjustment of hypoglycaemic medication between the statin and control groups [7].”
BackgroundInfluence of Pitavastatin on Glucose Tolerance in Patients with Type 2 Diabetes Mellitus
Yamakawa, T., Takano, T., Tanaka, S., Kadonosono, K., & Terauchi, Y. (2008) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e562 · Cited by 109 · cited 3×
“However, most studies were either observational studies or uncontrolled trials, were small in size and had short follow-up periods limiting the available evidence to delineate the effect of statins on glycaemic control in diabetes [10, 17].”
BackgroundResultMabuchi, H., Higashikata, T., Kawashiri, M., Katsuda, S., Mizuno, M., Nohara, A., Inazu, A., Koizumi, J., & Kobayashi, J. (2005) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.12.111 · Cited by 102 · cited 1×
“In addition, statins may be associated with increased insulin resistance [4, 17, 37–41].”
BackgroundRecommendation for term and measurement unit for “HbA1c”
Nordin, I. F. O. C., & Dybkær, R. (2007) · Clinical Chemical Laboratory Medicine · doi:10.1515/cclm.2007.245 · Cited by 92 · cited 1×
“mean difference in HbA1c concentration) in both traditional units (as percentages) and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) units (as mmol/mol) [30].”
BackgroundEffects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes—the CORALL study
Şimşek, S., Schalkwijk, C., & Wolffenbuttel, B. H. R. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03553.x · Cited by 92 · cited 1×
“3% or less in patients with diabetes [7, 10–13], while other studies have reported no worsening or even a potential benefit of statins on the glycaemic control in patients with diabetes [14–16].”
BackgroundStatins: Is It Really Time to Reassess Benefits and Risks?
Goldfine, A. B. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1203020 · Cited by 82 · cited 1×
“In addition, statins may be associated with increased insulin resistance [4, 17, 37–41].”
BackgroundStatins: Beneficial or Adverse for Glucose Metabolism
Sasaki, J., Iwashita, M., & Kono, S. (2006) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.13.123 · Cited by 82 · cited 1×
“However, most studies were either observational studies or uncontrolled trials, were small in size and had short follow-up periods limiting the available evidence to delineate the effect of statins on glycaemic control in diabetes [10, 17].”
BackgroundHolman, R. R., Paul, S., Farmer, A., Tucker, L., Stratton, I. M., Neil, H. A. W., & on behalf of the AFORRD study group (2009) · Diabetologia · doi:10.1007/s00125-008-1179-5 · Cited by 81 · cited 1×
“Where a study had duplicate publications [19, 20], we selected the report with the largest number of participants [20].”
BackgroundGumprecht, J., Gosho, M., Budinski, D., & Hounslow, N. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01477.x · Cited by 81 · cited 2×
“However, various statin types and doses may have differing adverse effects on glycaemic control, as indicated in previous reports [11, 17, 18], as well as being implied in our study where we found a trend towards this, which may have attenuated the pooled effect in the current meta-analysis.”
BackgroundResultInfluences of Statins on Glucose Tolerance in Patients with Type 2 Diabetes Mellitus
Takano, T., Yamakawa, T., Takahashi, M., Kimura, M., & Okamura, A. (2006) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.13.95 · Cited by 52 · cited 2×
“However, various statin types and doses may have differing adverse effects on glycaemic control, as indicated in previous reports [11, 17, 18], as well as being implied in our study where we found a trend towards this, which may have attenuated the pooled effect in the current meta-analysis.”
BackgroundResultTajima, N., Kurata, H., Nakaya, N., Mizuno, K., Ohashi, Y., Kushiro, T., Teramoto, T., Uchiyama, S., & Nakamura, H. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.05.027 · Cited by 50
Chapman, M. J., Orsoni, A., Robillard, P., Hounslow, N., Sponseller, C. A., & Giral, P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.874989 · Cited by 44 · cited 1×
“3% or less in patients with diabetes [7, 10–13], while other studies have reported no worsening or even a potential benefit of statins on the glycaemic control in patients with diabetes [14–16].”
BackgroundKonduracka, E., Galicka-Latała, D., Cieślik, G., Rostoff, P., Fedak, D., Sieradzki, J., Naskalski, J. W., & Piwowarska, W. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00798.x · Cited by 41 · cited 3×
“Konduracka et al [22] DALI [27]a Neil et al [20]a”
BackgroundStatins and diabetes risk: Fact, fiction, and clinical implications
Rocco, M. B. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79a.12091 · Cited by 38 · cited 1×
“In addition, observation of differences in effect on glycaemic control among the various statins suggests that differences in potency and/or lipid solubility may be important [4].”
BackgroundLiu, P.-Y., Lin, L.-Y., Lin, H.-J., Hsia, C.-H., Hung, Y.-R., Yeh, H.-I., Wu, T.-C., Chen, J.-Y., Chien, K.-L., & Chen, J.-W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076298 · Cited by 38 · cited 1×
“3% or less in patients with diabetes [7, 10–13], while other studies have reported no worsening or even a potential benefit of statins on the glycaemic control in patients with diabetes [14–16].”
BackgroundNeil, H. A. W., Ceglarek, U., Thiery, J., Paul, S. K., Farmer, A. A., & Holman, R. R. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.09.013 · Cited by 25
Behounek, B. D., Mcgovern, M. E., Kassler-Taub, K., Markowitz, S., Bergman, M., & THE PRAVASTATIN MULTINATIONAL STUDY GROUP FOR DIABETES (1994) · Clinical Cardiology · doi:10.1002/clc.4960171009 · Cited by 21 · cited 3×
“Behounek et al [16] Freed et al [21]a Freed et al [21]a DALI [27]a DALI [27]a Fig.”
BackgroundMethodEffect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia
Kei, A. A., Liberopoulos, E., & Elisaf, M. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i6.365 · Cited by 11 · cited 1×
“3% or less in patients with diabetes [7, 10–13], while other studies have reported no worsening or even a potential benefit of statins on the glycaemic control in patients with diabetes [14–16].”
Background
Cited by
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., Goldstein, L. B., Chin, C., Tannock, L. R., Miller, M., Raghuveer, G., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 738
Sabatine, M. S., Leiter, L. A., Wiviott, S. D., Giugliano, R. P., Deedwania, P., De Ferrari, G. M., Murphy, S. A., Kuder, J. F., Gouni-Berthold, I., Lewis, B. S., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30313-3 · Cited by 603
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
PCSK9: From Basic Science Discoveries to Clinical Trials
Shapiro, M. D., Tavori, H., & Fazio, S. (2018) · Circulation Research · doi:10.1161/circresaha.118.311227 · Cited by 285
Mancini, G. B. J., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R. A., Ng, D., Pearson, G. J., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.01.003 · Cited by 250
Metadata
- Authors
- Erqou, S., Lee, C. C., & Adler, A. I.
- Affiliations
- Weill Cornell Medicine (US)
- University of Toronto (CA)
- Addenbrooke's Hospital (GB)
- Corresponding author
- Erqou, Sebhat
- Venue
- Diabetologia
- Published
- 2014-09-23
- Volume
- 57
- Issue
- 12
- Pages
- 2444-2452
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2140272923
- Cited by
- 126
- References
- 45
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 8 · 2023: 11 · 2022: 16 · 2021: 8 · 2020: 10 · 2019: 14 · 2018: 10 · 2017: 9 · 2016: 14 · 2015: 13 · 2014: 2
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Weill Cornell Medical College
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statins, diabetes mellitus, glycemic control, HbA1c, hyperglycemia, glucose-lowering medications, lipid-lowering therapy
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.